FDA stand on compounding criticized

Share this article:

Public Citizen has written FDA asking it to stop making “misleading” statements about pharmacy compounding that could lead healthcare providers to treat patients with compounded drugs without understanding that they are not as safe as FDA-approved drugs.

The group objects to agency announcements encouraging hospitals and other HCPs to buy medical products from registered compounding or outsourcing facilities. “Because compounded products are fundamentally higher-risk than FDA-approved products,” it said, “[HCPs] should only rely on compounded products after first carefully assessing whether an FDA-approved product is available.” It added that “not all [HCPs] are aware that they should be making this assessment.”

The organization said it was concerned by a December blog post in which FDA commissioner Margaret Hamburg wrote that the agency “will be encouraging [HCPs] and health networks to consider purchasing compounded products from facilities that are registered with FDA.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets